Who founded Bright Peak Therapeutics?

Bright Peak Therapeutics was founded by Vijaya Pattabiraman, Jeffrey Bode in 2019.

Who are Bright Peak Therapeutics's investors?

Bright Peak Therapeutics's investors include RA Capital, Johnson & Johnson Innovation – JJDC, Versant Ventures, Venrock, Fidelity Investments, Invus, Qatar Investment Authority.

How much funding has Bright Peak Therapeutics raised?

Bright Peak Therapeutics has disclosed $196.5M raised across 2 of its 3 known rounds.

Where is Bright Peak Therapeutics headquartered?

Bright Peak Therapeutics is headquartered in San Diego, US.

Bright Peak Therapeutics

San Diego, US · Founded 2019 · Delaware corporation · 33 employees on LinkedIn · 7 known investors

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform. The company operates in the immuno-oncology drug development space.

Biotech Healthtech

Founders & leadership

Bright Peak Therapeutics was founded in 2019 by Vijaya Pattabiraman and Jeffrey Bode.

Vijaya PattabiramanCo-founder & Chief Technology Officer

Jeffrey BodeScientific Co-founder

Fredrik WiklundChief Executive Officer

Christine SiuNamed on SEC filing

Michael RosenzweigNamed on SEC filing

Bertolt KreftNamed on SEC filing

Board

Tom Woiwode inBoard directorManaging Director at Versant Ventures

Alexander Mayweg in 𝕏Board MemberManaging Director at Versant Ventures

Josh ResnickBoard director

Investors · 7

RA Capital✓ verifiedBoston

Johnson & Johnson Innovation – JJDC✓ verifiedNew Brunswick

Versant Ventures✓ verifiedSan Francisco · $250K – $5Mvia Alex Mayweg · board

VenrockPalo Alto · $500K – $10M

Fidelity InvestmentsreportedBoston

InvusreportedNew York

Qatar Investment AuthorityreportedDoha

Reported raises · per SEC filings

Form D private placements

$196.5M disclosed across 2 of 3 rounds · 2021–2025

▶$90MraisedJun 2024 · 21 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Bertolt KreftExecutive Officer
Laura ShawverDirector
Tom WoiwodeDirector
Vijaya PattabiramanExecutive Officer
Matthew RobbinsExecutive Officer
Leena GandhiDirector
Asish XavierDirector
Christine SiuDirector
Fredrik WiklundExecutive Officer, Director
Emily MinkowDirector
Jon WiggintonExecutive Officer
Jacob ChackoDirector

Offering amount: $90M
Amount sold: $90M
First sale: May 2024
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$106.5MraisedJun 2021 · 17 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Fredrik WiklundExecutive Officer, Director
Christine SiuDirector
Michael RosenzweigDirector
Bertolt KreftExecutive Officer
Tom WoiwodeDirector
Alexander MaywegDirector
Josh ResnickDirector

Offering amount: $106.5M
Amount sold: $106.5M
First sale: May 2021
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

bright-minds4 shared keywordsBright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform. The company targets central nervous system and brain disorders through serotonin regulation.

ブライトパス・バイオ㈱4 shared keywordsBrightPath Bio develops novel cancer immunotherapy medicines and cell therapy treatments that enhance the body's natural immune response to eliminate cancer cells. The company builds a platform for developing cell and antibody therapeutics across different cancer types and target antigens, with plans to expand into other immune-modulation therapeutic areas.

Companies competing with Bright Peak Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Bright Peak Therapeutics secures investment of 90 million US dollars | S-GEs-ge.com · Nov 2025

Bright Peak Raises $90M Series C - San Diego Business Journalsdbj.com · Jun 2024

Bright Peak Therapeutics: USD 90 million financing to advance immunoconjugate program – Swiss Biotechswissbiotech.org · Jun 2024

Bright Peak Therapeutics Raises $107M to Advance Cytokine Engineering - TimmermanReport.comtimmermanreport.com · Jun 2021

Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors - Bright Peak Therapeuticsbrightpeaktx.com · Jun 2021

About - Bright Peak Therapeuticsbrightpeaktx.com · Mar 2021

Frequently asked questions

What does Bright Peak Therapeutics do?: Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform. The company operates in the immuno-oncology drug development space.
Who founded Bright Peak Therapeutics?: Bright Peak Therapeutics was founded by Vijaya Pattabiraman, Jeffrey Bode in 2019.
Who are Bright Peak Therapeutics's investors?: Bright Peak Therapeutics's investors include RA Capital, Johnson & Johnson Innovation – JJDC, Versant Ventures, Venrock, Fidelity Investments, Invus, Qatar Investment Authority.
How much funding has Bright Peak Therapeutics raised?: Bright Peak Therapeutics has disclosed $196.5M raised across 2 of its 3 known rounds.
Where is Bright Peak Therapeutics headquartered?: Bright Peak Therapeutics is headquartered in San Diego, US.